From a molecular therapeutic perspective, Relafen 750 (naproxen sodium) represents a fascinating illustration of how targeted drug action can reduce discomfort. Its mechanism primarily involves the blocking of cyclooxygenase (COX), specifically COX-2, diminishing the production of pain messengers. This selective inhibition, while aiming to avoid ga

From a biochemical pharmacy viewpoint, Relafen 750, containing naproxen, embodies a fascinating case study in therapeutic action. Its chief mechanism involves inhibiting cyclooxygenase (COX) enzymes, specifically COX-2, which contributes reduced generation of inflammatory mediators . This selective inhibition alleviates swelling and pain associated